| | | | | By Nick Brown, Deena Beasley, Gabriela Mello and Alexander Cornwell | | |
| | | Here's what you need to know about the coronavirus right now: | | |
| | | Scientists are only starting to grasp the vast array of health problems caused by the novel coronavirus, some of which may have lingering effects on patients and health systems for years to come, according to doctors and infectious disease experts. | | |
| | | As South America's winter sets in, health officials and doctors are beefing up inoculation programs to head off a potential spike in seasonal flu that could overwhelm hospitals already straining under the coronavirus pandemic. | | |
| | | As face coverings become the norm amid the coronavirus pandemic, Japanese startup Donut Robotics has developed an internet-connected "smart mask" that can transmit messages and translate from Japanese into eight other languages. | | |
| | | As face coverings become the norm amid the coronavirus pandemic, Japanese startup Donut Robotics has developed an internet-connected "smart mask" that can transmit messages and translate from Japanese into eight other languages. | | |
| | | South Korea has added Gilead's anti-viral drug remdesivir to its coronavirus treatment guidelines in its first revision of recommendations since the outbreak began and urged caution in the use of the steroid therapy dexamethasone. | | |
| | | Indonesia reported 1,240 new coronavirus infections on Friday, taking the total number of cases to 51,427. | | |
| | | Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. | | |
| | | Russia on Friday reported 6,800 new coronavirus cases, the first daily rise below 7,000 since late April, taking its nationwide tally to 620,794. | | |
| | | Molecular Partners aims to test its COVID-19 drug candidate on people later this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes that project will help it recover from the failure of its eye drug abicipar. | | |
|
| |
